Analyzing Lucid Diagnostics (NASDAQ:LUCD) and Sight Sciences (NASDAQ:SGHT)

Lucid Diagnostics (NASDAQ:LUCD) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.

Risk and Volatility

Lucid Diagnostics has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500.

Profitability

This table compares Lucid Diagnostics and Sight Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-1,476.35%	N/A	-120.43%
Sight Sciences	-64.23%	-59.38%	-36.43%

Insider and Institutional Ownership

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 6.8% of Lucid Diagnostics shares are held by insiders. Comparatively, 30.9% of Sight Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Lucid Diagnostics and Sight Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	0	0	5	0	3.00
Sight Sciences	0	4	3	0	2.43

Lucid Diagnostics currently has a consensus target price of $3.65, suggesting a potential upside of 257.84%. Sight Sciences has a consensus target price of $4.42, suggesting a potential upside of 29.52%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, research analysts clearly believe Lucid Diagnostics is more favorable than Sight Sciences.

Earnings and Valuation

This table compares Lucid Diagnostics and Sight Sciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.35 million	25.44	-$45.53 million	($1.19)	-0.86
Sight Sciences	$79.87 million	2.24	-$51.51 million	($0.96)	-3.55

Lucid Diagnostics has higher earnings, but lower revenue than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Summary

Lucid Diagnostics beats Sight Sciences on 8 of the 14 factors compared between the two stocks.

About Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

About Sight Sciences

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.